These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 7803895)

  • 1. Fluvastatin cost considerations.
    Garnett WR
    Ann Pharmacother; 1994 Sep; 28(9):1111-2. PubMed ID: 7803895
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost of lipid-lowering statin drugs.
    Gotto AM; Hay JW
    Am J Cardiol; 1996 Jan; 77(2):225-6. PubMed ID: 8546104
    [No Abstract]   [Full Text] [Related]  

  • 3. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Which statin is more efficient? Concepts and applications in economic evaluation].
    García-Altés A; Jovell AJ
    Aten Primaria; 2000 Sep; 26(5):333-8. PubMed ID: 11100606
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
    Masters P; Shetty A
    BMJ; 1996 Nov; 313(7065):1143; author reply 1144. PubMed ID: 8916710
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
    Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
    Smart AJ; Walters L
    S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managed care trends in statin usage.
    Bazalo GR
    Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the cost-effectiveness of lipid-lowering therapy.
    Jacobson TA; Schein JR; Williamson A; Ballantyne CM
    Arch Intern Med; 1998 Oct; 158(18):1977-89. PubMed ID: 9778197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
    Begg E; Sidwell A; Gardiner S; Nicholls G; Scott R
    N Z Med J; 2003 Mar; 116(1170):U360. PubMed ID: 12658318
    [No Abstract]   [Full Text] [Related]  

  • 13. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The change of cost: reference-based pricing and the statins.
    Thomas M
    Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluvastatin: what is the evidence?
    Bagg W; Braatvedt G
    N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
    [No Abstract]   [Full Text] [Related]  

  • 17. Response from PHARMAC: difficult choices.
    Moodie P; Metcalfe S; McNee W
    N Z Med J; 2003 Mar; 116(1170):U361. PubMed ID: 12658319
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching statins: can we do harm?
    Thomas U
    N Z Med J; 1998 Jan; 111(1058):18. PubMed ID: 9490420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.